Epoprostenol injection
Products billed under this code include Epoprostenol, Flolan, Veletri.
Payment limit per 0.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Epoprostenol, Flolan, Veletri.
Payment limit per 0.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Epoprostenol | Sun Pharmaceutical Industries, Inc. | 62756-0059-40 | 1 | $17.247 |
| Epoprostenol | Sun Pharmaceutical Industries, Inc. | 62756-0060-40 | 3 | $51.741 |
| Epoprostenol | Mylan Institutional LLC | 67457-0587-10 | 1 | $17.247 |
| Epoprostenol | Mylan Institutional LLC | 67457-0588-10 | 3 | $51.741 |
| Flolan | GlaxoSmithKline LLC | 00173-0517-00 | 1 | $17.247 |
| Flolan | GlaxoSmithKline LLC | 00173-0519-00 | 3 | $51.741 |
| Veletri | Actelion Pharmaceuticals US, Inc. | 66215-0402-01 | 3 | $51.741 |
| Veletri | Actelion Pharmaceuticals US, Inc. | 66215-0403-01 | 1 | $17.247 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $17.247 | +$0.329 | 0.5 MG | Epoprostenol injection | v1, posted September 17, 2026 |
| 3Q26 | $16.918 | +$2.042 | 0.5 MG | Epoprostenol injection | v1, posted September 15, 2026 |
| 2Q26 | $14.876 | −$0.778 | 0.5 MG | Epoprostenol injection | v1, posted September 15, 2026 |
| 1Q26 | $15.654 | −$0.545 | 0.5 MG | Epoprostenol injection | v1, posted September 15, 2026 |
| 4Q25 | $16.199 | −$0.001 | 0.5 MG | Epoprostenol injection | v1, posted September 8, 2026 |
| 3Q25 | $16.20 | +$0.125 | 0.5 MG | Epoprostenol injection | v1, posted March 10, 2026 |
| 2Q25 | $16.075 | −$0.361 | 0.5 MG | Epoprostenol injection | v1, posted March 10, 2026 |
| 1Q25 | $16.436 | +$0.576 | 0.5 MG | Epoprostenol injection | v1, posted December 19, 2025 |
| 4Q24 | $15.86 | −$0.614 | 0.5 MG | Epoprostenol injection | v1, posted June 11, 2025 |
| 3Q24 | $16.474 | +$0.826 | 0.5 MG | Epoprostenol injection | v1, posted June 11, 2025 |
| 2Q24 | $15.648 | −$0.314 | 0.5 MG | Epoprostenol injection | v1, posted March 11, 2025 |
| 1Q24 | $15.962 | −$0.061 | 0.5 MG | Epoprostenol injection | v1, posted December 19, 2024 |
| 4Q23 | $16.023 | +$0.024 | 0.5 MG | Epoprostenol injection | v1, posted October 10, 2024 |
| 3Q23 | $15.999 | +$0.226 | 0.5 MG | Epoprostenol injection | v1, posted June 5, 2024 |
| 2Q23 | $15.773 | +$0.573 | 0.5 MG | Epoprostenol injection | v1, posted February 23, 2024 |
| 1Q23 | $15.20 | −$0.656 | 0.5 MG | Epoprostenol injection | v1, posted December 6, 2023 |
| 4Q22 | $15.856 | +$0.088 | 0.5 MG | Epoprostenol injection | v1, posted June 22, 2023 |
| 3Q22 | $15.768 | −$0.523 | 0.5 MG | Epoprostenol injection | v1, posted June 9, 2023 |
| 2Q22 | $16.291 | +$0.031 | 0.5 MG | Epoprostenol injection | v1, posted December 14, 2022 |
| 1Q22 | $16.26 | +$0.055 | 0.5 MG | Epoprostenol injection | v1, posted June 8, 2022 |
| 4Q21 | $16.205 | −$0.016 | 0.5 MG | Epoprostenol injection | v1, posted June 2, 2022 |
| 3Q21 | $16.221 | −$0.231 | 0.5 MG | Epoprostenol injection | v1, posted June 2, 2022 |
| 2Q21 | $16.452 | +$0.024 | 0.5 MG | Epoprostenol injection | v1, posted March 1, 2022 |
| 1Q21 | $16.428 | – | 0.5 MG | Epoprostenol injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.